DK1003552T3 - LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation - Google Patents
LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferationInfo
- Publication number
- DK1003552T3 DK1003552T3 DK97936112T DK97936112T DK1003552T3 DK 1003552 T3 DK1003552 T3 DK 1003552T3 DK 97936112 T DK97936112 T DK 97936112T DK 97936112 T DK97936112 T DK 97936112T DK 1003552 T3 DK1003552 T3 DK 1003552T3
- Authority
- DK
- Denmark
- Prior art keywords
- proliferation
- cd2a antibody
- inhibiting
- cell activation
- cd2a
- Prior art date
Links
- 230000006044 T cell activation Effects 0.000 title 1
- 230000006052 T cell proliferation Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/472,281 US5817311A (en) | 1993-03-05 | 1995-06-07 | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
| PCT/US1997/012645 WO1999003502A1 (fr) | 1995-06-07 | 1997-07-18 | ANTICORPS DIRIGE CONTRE LO-CD2a ET UTILISATION DE CELUI-CI POUR INHIBER L'ACTIVATION ET LA PROLIFERATION DES LYMPHOCYTES T |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1003552T3 true DK1003552T3 (da) | 2008-08-25 |
Family
ID=26792646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97936112T DK1003552T3 (da) | 1995-06-07 | 1997-07-18 | LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5817311A (fr) |
| EP (1) | EP1003552B1 (fr) |
| AT (1) | ATE395081T1 (fr) |
| AU (1) | AU754185B2 (fr) |
| CA (1) | CA2295604C (fr) |
| DE (1) | DE69738692D1 (fr) |
| DK (1) | DK1003552T3 (fr) |
| ES (1) | ES2307301T3 (fr) |
| HK (1) | HK1025738A1 (fr) |
| WO (1) | WO1999003502A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US7592006B1 (en) * | 1993-03-05 | 2009-09-22 | Université Catholique de Louvain | Composition comprising the LO-CD2a antibody |
| US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
| US6849258B1 (en) * | 1997-07-18 | 2005-02-01 | Universite Catholique De Louvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
| HUP0103563A3 (en) * | 1998-08-31 | 2004-04-28 | Biogen Idec Ma Inc Cambridge | Method of modulating memory effector t-cells and compositions |
| WO2000045842A2 (fr) | 1999-02-04 | 2000-08-10 | The General Hospital Corporation | Techniques d'allogreffe humaine |
| US6541611B1 (en) | 1999-06-18 | 2003-04-01 | Universite Catholique De Louvain | LO-CD2b antibody |
| US20040170635A1 (en) * | 2001-02-01 | 2004-09-02 | Vaishnaw Akshay K. | Methods for treating or preventing skin disorders using cd2-binding agents |
| US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| MXPA03007878A (es) * | 2001-03-02 | 2004-07-08 | Medimmune Inc | Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina. |
| AU2002320352A1 (en) * | 2001-07-24 | 2003-02-17 | Biogen Idec Ma Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| WO2003097697A2 (fr) | 2002-05-22 | 2003-11-27 | Esbatech Ag | Infrastructures immunoglobuliniques faisant preuve de stabilité accrue en environnement intracellulaire, et procédés d'identification correspondants |
| BRPI0507404A (pt) * | 2004-02-06 | 2007-06-26 | Astellas Us Llc | método de tratamento de um indivìduo que tem psorìase e kit |
| CA2565804A1 (fr) * | 2004-05-04 | 2005-12-01 | Genaissance Pharmaceuticals, Inc. | Marqueurs haplotypes et procedes d'utilisation de ceux-ci pour determiner la reponse a un traitement |
| CA2565259A1 (fr) * | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Polypeptide lfa-3 soluble destine a traiter de troubles viraux |
| EP1768662A2 (fr) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence |
| KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
| EP3115451A1 (fr) * | 2008-09-02 | 2017-01-11 | Pluristem Ltd. | Cellules adhérentes provenant d'un tissu placentaire et son utilisation en thérapie |
| SG11202110287QA (en) | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| WO2021005009A1 (fr) | 2019-07-05 | 2021-01-14 | Iomx Therapeutics Ag | Anticorps de liant à l'igc2 de l'igsf11 (vsig3) et leurs utilisations |
| EP4175668A1 (fr) | 2020-07-06 | 2023-05-10 | iOmx Therapeutics AG | Anticorps de liaison à l'igv d'igsf11 (vsig3) et leurs utilisations |
| WO2024077118A2 (fr) | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | Protéines multispécifiques et procédés associés |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| WO1991001752A1 (fr) * | 1989-07-27 | 1991-02-21 | Fred Hutchinson Cancer Research Center | Anticorps monoclonaux immunosuppresseurs, hybridomes et procedes de transplantation |
| US5283058A (en) * | 1990-08-30 | 1994-02-01 | The General Hospital Corporation | Methods for inhibiting rejection of transplanted tissue |
| US5858725A (en) * | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
| PT687300E (pt) * | 1993-03-05 | 2002-03-28 | Univ Catholique Louvain | Anticorpo lo-cd2a e sua utilizacao para a inibicao da activacao e proliferacao de celulas-t |
-
1995
- 1995-06-07 US US08/472,281 patent/US5817311A/en not_active Expired - Lifetime
-
1997
- 1997-07-18 AT AT97936112T patent/ATE395081T1/de active
- 1997-07-18 DE DE69738692T patent/DE69738692D1/de not_active Expired - Lifetime
- 1997-07-18 WO PCT/US1997/012645 patent/WO1999003502A1/fr active Application Filing
- 1997-07-18 AU AU38862/97A patent/AU754185B2/en not_active Ceased
- 1997-07-18 EP EP97936112A patent/EP1003552B1/fr not_active Expired - Lifetime
- 1997-07-18 ES ES97936112T patent/ES2307301T3/es not_active Expired - Lifetime
- 1997-07-18 DK DK97936112T patent/DK1003552T3/da active
- 1997-07-18 CA CA002295604A patent/CA2295604C/fr not_active Expired - Fee Related
-
2000
- 2000-08-08 HK HK00104946A patent/HK1025738A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2295604C (fr) | 2008-09-30 |
| WO1999003502A1 (fr) | 1999-01-28 |
| EP1003552B1 (fr) | 2008-05-14 |
| AU754185B2 (en) | 2002-11-07 |
| CA2295604A1 (fr) | 1999-01-28 |
| EP1003552A4 (fr) | 2002-10-02 |
| ES2307301T3 (es) | 2008-11-16 |
| ATE395081T1 (de) | 2008-05-15 |
| US5817311A (en) | 1998-10-06 |
| DE69738692D1 (de) | 2008-06-26 |
| EP1003552A1 (fr) | 2000-05-31 |
| HK1025738A1 (en) | 2000-11-24 |
| AU3886297A (en) | 1999-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1003552T3 (da) | LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation | |
| NO962346L (no) | Humaniserte antistoffer og anvendelser derav | |
| DK0859957T3 (da) | Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling | |
| ATE415173T1 (de) | Pan dr-bindeproteinen zur erhöhung der immunantwort | |
| ATE255126T1 (de) | Unterdrückung von immunantwort durch hemmung von cathepsin s | |
| ATE132197T1 (de) | Monoklonale antikörper | |
| EP0313378A3 (fr) | Méthodes et compositions pour l'elimination temporaire d'anticorps immuns humoraux | |
| DK0687300T3 (da) | LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation | |
| DK0969873T3 (da) | Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf | |
| AU2002223462A1 (en) | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28 | |
| DK0610335T3 (da) | Fremgangsmåder til udformning af rekombitope peptider | |
| DK0812206T3 (da) | Fremgangsmåde til stimulering af en immunrespons | |
| NO922621D0 (no) | Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav | |
| DE60042941D1 (de) | Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten | |
| HK1021318A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation | |
| DK1021196T3 (da) | Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion | |
| DE69839943D1 (de) | Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen | |
| NO972522L (no) | Monoklonale antistoffer med immunoundertrykkende aktivitet | |
| ATE245661T1 (de) | Natürliche menschliche igm antikörper | |
| ATE156711T1 (de) | Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm) | |
| Lehner et al. | Cell-bound helper and suppressor factors in primate lymphocytes. | |
| DK0854727T3 (da) | Tumorafstødelsesantigener, der præsenteres af HLA-B44-molekyler, og anvendelser af samme | |
| Minai et al. | Mechanism of IL-10 Production by a CD8+ T Cell Clone | |
| DK0597043T3 (da) | Porcine adipocytantigener og deres anvendelse til immunologisk bekæmpelse af fedt |